Pfizer's BRAFTOVI Combo Nearly Doubles PFS In BRAF V600E Metastatic Colorectal Cancer

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced detailed progression-free and overall survival results from Cohort 3 of the Phase 3 BREAKWATER trial. This randomized cohort evaluated BRAFTOV...